Why pre-screen gene therapy researchers before the interview
A promising result in this field is usually a batch effect, a titre difference or an animal that happened to respond. Finding out costs months, which is why the researchers who move fastest are the ones who repeat before they believe. Add work with viral vectors, where containment practice is not optional, and the screen has two clear targets. A short screen asks about a result that did not repeat and what caused it.
What actually matters when screening Gene Therapy Researcher candidates
- 01
Technique and experimental design
Probe hands-on command of vector work: AAV serotype selection, lentiviral packaging, plasmid design, ddPCR titration, potency assays, and how they powered in vivo dosing cohorts.
- 02
Results that went somewhere
Ask which constructs or programmes moved forward: IND-enabling packages, transfer to GMP or CDMO, published editing efficiencies, licensed candidates, or programmes they helped kill on data.
- 03
Troubleshooting and reproducibility
Test troubleshooting of low transduction, empty:full capsid ratios, off-target editing calls, batch variability in cell lines, and how they re-established reproducible results across operators.
- 04
Documentation and collaboration
Check ELN discipline, protocol writing for IACUC or ethics submissions, biosafety committee interaction, and working with vector core, analytics, and regulatory colleagues on shared timelines.
Pre-screening questions to ask Gene Therapy Researcher candidates
12 questions grouped by what they test. Ask the same set in every screen and score answers on a consistent scale, or send them as an async video screen and compare answers side by side.
Work at the bench
3 questions01Have you conducted in vivo studies for gene therapy applications?
Listen forStudies they performed with dosing, endpoints and controls described, including approvals that were required.
Animal work described from a distance, or no involvement in study design or approval processes.
02Can you explain your experience with animal models in this research?
Listen forModel limitations understood honestly, including where translation to human disease is known to be weak.
Model results presented as directly predictive, or no awareness of where a model fails.
03How proficient are you with cell culture techniques in this context?
Listen forSterile technique and cell line authentication treated as routine, with mycoplasma testing done rather than assumed.
Cell lines used without authentication, or contamination testing left to someone else entirely.
Vectors and delivery
4 questions04Can you describe your experience with vector design and development?
Listen forVectors they designed and produced, with promoter choice, packaging limits and titre determination explained.
Vectors always obtained ready-made, or design constraints such as packaging capacity not understood.
05Can you discuss your proficiency with different gene delivery methods?
Listen forDelivery chosen for tissue and duration, with immune response and tropism considered as design constraints.
One delivery method used regardless of target, or immune responses not treated as a real problem.
06Have you worked with non-viral delivery systems?
Listen forPractical experience with the efficiency and toxicity trade-offs, and where these systems currently fall short.
Non-viral methods described only from the literature, or their efficiency limits not acknowledged.
07How familiar are you with current gene editing technologies?
Listen forEditing performed hands-on, with off-target assessment and editing efficiency measured rather than assumed.
Off-target effects not assessed, or editing efficiency reported without a measurement method.
Reproduced before believed
3 questions08How do you ensure reproducibility and accuracy in your experimental results?
Listen forIndependent repeats with appropriate controls, and results held until they reproduce across batches.
Single experiments reported as findings, or replicates that are technical rather than biological.
09Can you describe a challenging problem in your research and how you overcame it?
Listen forA real failure such as inconsistent titres or an unrepeatable effect, traced systematically to its cause.
Difficulties described as resourcing, or no experiment that produced an unexplained result.
10How do you manage and document data from your experiments?
Listen forRecords kept so another researcher could repeat the work exactly, with raw data retained and versioned.
Records that only make sense to the person who wrote them, or raw data discarded after analysis.
Biosafety and regulation
2 questions11What safety protocols do you follow when working with viral vectors?
Listen forContainment level, waste handling and exposure procedure described specifically without needing to be prompted.
Safety answered as protective equipment alone, or containment requirements described vaguely.
12What regulatory considerations do you keep in mind in this research?
Listen forAwareness of what translation requires, so early work is done in a way that supports later filings.
Regulation treated as a later problem, or no understanding of what evidence a filing needs.
How to score responses
Score every candidate on the same four criteria immediately after the screen. At this stage you are shortlisting for panel interviews, not making the final call.
Technique and experimental design
35%5Names specific serotypes, promoters and capsid variants used, explains titre methods, and justifies dose ranging with control arms and endpoints.
Results that went somewhere
25%5Points to a named candidate advanced to IND-enabling tox, GMP tech transfer, or publication, with their own contribution clearly bounded.
Troubleshooting and reproducibility
25%5Traces a real failure to root cause (capsid ratio, MOI drift, passage number) and describes the controls that confirmed the fix.
Documentation and collaboration
15%5Describes audit-ready ELN records, authored IACUC or IBC protocols, and concrete handoffs to analytics or process development teams.
A promising result is usually a batch effect, and finding out costs months. A one-way video screen asks about one that did not repeat.
Try it on HirevireScreening FAQ
Process basics
How long should a pre-screening round for this role take?
Fifteen minutes across eight to ten questions, answered async. Enough to establish bench work they performed, test their vector and delivery knowledge, and check reproducibility and safety practice.
How much should publications count?
As evidence of contribution, not as a score. Ask what they personally did on a paper. Author position tells you less than a clear account of which experiments were theirs.
Evaluating answers
What is the strongest signal when screening this role?
A result that did not repeat and what caused it. Researchers with real bench time have several. Anyone whose experiments always worked has either been lucky or has not looked closely.
How do I judge their safety practice?
Ask about working with viral vectors. Sound answers cover containment level, waste handling and exposure procedure without prompting. Vagueness here is disqualifying for laboratory work.
Go deeper on this role
Sanat has been hiring since 2012 and watching the recruitment industry change up close ever since, and turned that screening process into Hirevire's video screening platform. LinkedIn
